The phase II JULIET trial suggests that the CD19-targeting CAR T-cell therapy 
tisagenlecleucel produces durable responses in patients with relapsed and 
refractory diffuse large B-cell lymphoma. Three months after the therapy, 32% of 
the patients showed complete responses and 6% showed partial responses. After 6 
months, those rates were 30% and 7%.